SLC30A8 and type 2 diabetes mellitus: We performed deep phenotyping studies on SLC30A8 LoF heterozygotes and homozygotes in the largest recall-by-genotype study for SLC30A8 to date, and the first to include human knockouts of SLC30A8. With a completion rate of 54.7%, this study represents a significant advance over recently reported recall frameworks for type 2 diabetes [52].